Connect with us

Cannabis News

The Fight For Cannabis Reform Must Focus On Medical Patients—Not Taxes And Banking—In Order To Win (Op-Ed)

Published

1 year ago

on

“Without medicine at the center, the Federal reform loses its moral compass and its political lever.”

Cannabis Businesses and Professionals Unity for the National Medical Kannabis

It is clear that the opposition against cannabis is nourished by the narrative of moral panic, disinformation and “large marijuana”. Without strategic contracting for well-being, we risk losing the land we have earned.

Last week, the HOUSE’s paving committee exceeded the version of the Budget of the Department of Justice. FY2026 Trade, Justice, Science and Related Agency (CJS) would include provisions that will allow the administration of drug enforcement administration (DEA) again in the states of cannabis programs.

CJS Budget Bill was the language that would also want Prevent President Donald Trump to make efforts for determination in cannabis programming. This should turn off alarms in our community. And yet the loudest push came from business, but from patients, with our uncompromise, farms, allies.

Our most valuable asset

The coverage coverage coverage for Kannabis was a promise to produce “determination” for a few weeks. But there was a real bearer What he said about Kannabis: “great thing about medicine” listens.

These words catch true in Washington, DC: Cannabis doctor remains the most politically feasible policy for federal policy reform. If you currently face cannabis businesses and professionals, we cannot ignore the truth.

Bank and tax relief will not come with a great reform of cannabis

Despite the flood of new State laws, new businesses and new participants, Washington barely made.

It has been more than a decade to secure access to Secure access (ASA) to ensure the fire interference in the Medical State of Congress. Bank reform, tax fairness and state trade are still not available. Patients remain access to stigma, discrimination and patches.

Corporate Kornabis seemed to be supported by the medical expansion and cannabis business, who walks far from the patient’s narrative. It was the descendant of the Department of Health and Human Services (HHS), Cannabis “admits that he currently supports” medical use “and will lead to the III program.

Instead of taking a return of victory for medical cannabis, the cannabis community was based on tax deductions.

This pivot has been able to provide short-term growth and attention, but he actually canceled the proven path that has moved Congress: patients. The result is a decade of Washington.

Without a medical cannabis in the center, the Federal reform loses its moral compass and a political lever.

Including the “big things” about medical cannabis

Medical cannabis is the strongest counterpoint. It saves lives, reduces health costs and undergo public support during the political spectrum.

Consider the numbers:

  • Chronic pain: Almost 30% of chronic pain patients use cannon to relieve, often reduce or replace opioids. More than 68 million Americans live with chronic pain.
  • Cancer: More than 40% of cancer reports the symptoms such as pain, anxiety, sleep and hunger.
  • Older adults: One of the five adults now uses cannabis now. In the medical states, many advantages made by many arthritis, sleep and quality of life. It is the fastest increase in Kannabis users.
  • Veterans: About 22 percent of veterans use PTSD, chronic pain and sleeping incidents, still facing stigma and federal obstacles.
  • Opioids: Washington Post recently mentioned the study County with dispensers will be seen reducing 30 percent of the dead Opioido overdose over time.

Pay page

If you entered the Kannabis space in the last five years or 10 years, you may not know how we arrived.

Patient advocates have been working on strategies for decades for the National Medical Canavy Program.

For years, the cannabis supply chain programs, cannabis supply chain products, the World Cannabis Organization (UN) and the United Nations, and the United Nations, recommends patients for medical professionals.

White House This year decreased these protections, Asa called the organizations of national patients and encouraged Congress to restore them. And HHS can Cannabis “use medical use” at this time? Reflects more than two decades established by patient defenders.

Not to choose zero sum

Helping Medical Kannabis does not mean against adult use. In fact, focusing the doctor strengthens the whole market.

Patients bring credibility with politicians, their stories create support for bipartisan and their experiences cannot be divided into quarter sales figures.

President Trumpen comments – “Great things about doctors” – they are not just a note. In the policy of Kannabis, they reflect coherent thread in administrations, festivals and decades: the medical cannabis has had power.

If we become “great things”, we can change the conversation, go back and finally, we will finally get comprehensive federal realms of patients.

Patients have a plan; They need our help

As a creative founder of safe access, Steph Sherer described the last marijuana at the moment. “It’s time for the congress to create a federal path for medical cannabis accesses” The next phase of access is a comprehensive federal legislation. History has shown us that the doctor must first come.

Patients created a moral and political basis for cannabis reform. Today they remain the strongest motor. But only patients cannot carry this fight. If we want to move Washington, we need to put patients and their needs behind our efforts.

Cannabis businesses and professionals united for the national medical cannabis It is safe access to access security (ASA) interested business, professionals and investors who believe in cannabis medicine and are willing to end the patients.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Fluent to sell New York license and operations

Published

2 months ago

on

July 30, 2026

By











Fluent has entered into a definitive agreement to sell Etain, LLC, the Company’s New York-based operating entity. The purchase agreement was signed on July 22, 2026. The transaction provides for the sale of Etain’s Registered Entity license, certain of the Company’s New York operating assets and related New York leases for cash, subject to customary purchase price adjustments.

The Company believes the Transaction advances its strategic objectives and expects the Transaction to comply with applicable regulatory requirements in connection with the Company’s previously announced plan of arrangement for Vireo Growth Inc. (the “Deal”) while providing for an orderly transition of the New York operations to an experienced operator committed to serving patients and consumers.

Completion of the free transaction is subject to closing conditions, including, among other customary conditions, approval of the change in ownership by the New York State Cannabis Control Board and the completion of all conditions to the completion of the Agreement.

For more information:
FLUENT Corp
getfluent.com/










Continue Reading

Cannabis News

Marijuana Has ‘Horrific Health Risks’ And No Medical Value, Former Trump Attorney General Claims

Published

2 months ago

on

July 30, 2026

By

A former US attorney general who served in President Donald Trump’s first term says marijuana poses “tremendous health risks,” has no medical value and should not be rescheduled under federal law.

“Marijuana redistricting would create a false impression that it is safe, reduce penalties for illegally selling the drug, and provide a large tax windfall to those who legally supply it,” William Barr wrote in a Wednesday op-ed for The Washington Post, Kevin Sabet, CEO of the prohibitionist organization Smart Approaches to Marijuana. “That would be a disaster.”

The opinion comes as the Trump administration moves forward with cannabis reregulation.

According to an order issued in April by US Attorney General Todd Blanche, Marijuana products regulated by a state medical cannabis license were immediately changed from Schedule I As did marijuana products approved by the Food and Drug Administration (FDA) under Schedule III of the Controlled Substances Act (CSA).

an administrator The hearing is looking at the broader rescheduling of marijuanawith The Drug Enforcement Administration (DEA) has been tasked with advocating for cannabis reform highlighting the testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids. It included appearances by a Food and Drug Administration (FDA) scientist and a doctor from New Hampshire. Medical marijuana provides relief to pain patients and can serve as an alternative to opioids.

But Sabet and Barr, who served as Trump’s attorney general from 2019-2020, argued that “the evidence presented at the hearing did not support the rescheduling of marijuana” and instead “confirmed what decades of data have shown: raw marijuana has no scientifically established medical value and is highly susceptible to abuse.”

After the parties to the hearing have filed termination rights, the DEA administrative law judge overseeing the proceedings will make a recommendation regarding rescheduling, and the agency administrator will make a final decision.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling supporters that they do not meet the definition of “interested person” to participate because they have not been “affected or prejudiced by any rule or proposed rule that may be issued.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

The former attorney general’s new opinion says “the stakes couldn’t be higher”, arguing that “marijuana today is more dangerous than ever” and that it is “addictive”, throwing out a list of alleged harm to mental and physical health.

“These unhealthy effects are a predictable result of a powerful and addictive drug being normalized, commercialized and marketed as a medicine,” Barr and Sabet say. “It would be one thing if marijuana had medical value. But there is no credible evidence that marijuana is an effective treatment for any medical condition, despite the millions of dollars spent trying to prove otherwise.”

The Department of Health and Human Services (HHS) published a 252 analysis in 2023 that concluded that marijuana had accepted medical value and should be rescheduled.

The new opposition piece also says that “rescheduling would unlock enormous revenue for the corporate marijuana industry by bringing it into a category that has not been covered by a longstanding reduction in federal drug tax deductions,” referring to a law known as 280E, which repeals Sections I and II.

“This, in turn, would allow the industry to spend even more on advertising and marketing to young people,” Barr and Sabet. he wroteArguing that “those who would lose this dragon in society are laying the foundations for another Big Tobacco”.

The Sabet organization, SAM, is one of several parties Challenging the Marijuana Redistricting Process which have been upheld by a federal Court of Appeals. those separate parts State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

SAM’s lawsuit was signed by attorneys at Torridon Law PLLC, where Barr is a partner.

The team announced in January that it was Hiring Barr’s firm to fight cannabis rescheduling After Trump signed an executive order directing officials to quickly complete the process.

During the first Trump administration, Barr was accused by a Justice Department official Directing improper anti-company investigations into multiple cannabis company mergers– Accounting for almost a third of the division’s cases in 2019.

Several Democratic members of Congress introduced a resolution calling for an investigation into Barr’s possible impeachment, saying “abused the power of his office” to improperly investigate marijuana businesses while engaging in other allegedly illegal conduct.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

How much red light does cannabis really need?

Published

2 months ago

on

July 26, 2026

By

When growers pull out two LED fixtures side by side, the first number they usually discuss is percent red. This is an easy specification to fix. They are efficient at producing red photons and incredibly efficient at photosynthesis, and cannabis eats away at the flower. So more red must be better, right?

Not so simple. Red is an input to a spectrum, and the spectrum is an input to a room. There is no single spectrum that wins everywhere. An indoor room pushes hard, a greenhouse that soaks up sunlight, a temperamental cultivar, and aggressive yields call for something different. Knowing what each light strip actually does allows you to choose a tool that fits your grow instead of one that just has a big number on the sales page.

© JumpLights

Blue: structure
Blue (approximately 400-500 nm) gives shape to the plant. It maintains dense growth, strong stems, tight internodes and allows it to develop as desired. It also encourages stomatal opening, so the plant manages water and gas exchange better. Get blue and you’ve built a plant that can carry heavy flowers with no problem.

Green: access
Green was eliminated as the wavelength is “reflected” by plants. It turns out that it does a real job. Blue and red are absorbed above; the green goes deep into the fat and reaches the leaves that are never touched by the above photons. In a compact room, it’s the difference between plants photosynthesising from the top down and those that work only from the top. Green won’t replace your red or blue, but it does carry usable light where they can’t reach.

Red: engine
Red is the horse of the flower. It absorbs as efficiently as anything in the spectrum, and is responsible for most of the biomass you’re after. Redder generally means faster flower development, more weight and better efficiency per watt.

But red has a ceiling, and it’s tied to what you run. Push PPFD upwards with a heavy red spectrum and some cultivars begin to whiten at the top: the flower should be dense with pale, washed tips. Genetics, intensity, barrel temperature and your general environment all feed into it. If you’re using aggressive light levels, a lower red spectrum will buy you room before that becomes a problem, leaving you almost no photosynthetic punch to get it.

Far Red: More than Emerson
Far-red (700-750 nm) appears in more devices every year. It contributes little to photosynthesis on its own, but it moves plant morphology and works with red through the Emerson Enhancement Effect. Used properly, it helps to deepen the light, encourage uniformity of the canopy and encourage the response of the bloom. The key word is small. A touch of far red rounds out a spectrum; he’s not there to make a show.

Matching the red percentage with the room
Cannabis addresses the entire spectrum, not a line on a spec sheet. Reds cause flowers, but blues, greens and crimsons give the plant something it needs. Where you land in red refers to how you grow.

A lower red spectrum (30-40%) captures more blue and green, gives you better morphology, reduces the risk of photobleaching, and holds up when you’re running extreme PPFD. Moderate spectrum (40-55%) is the sweet spot in commercial greenhouses: strong photosynthetic efficiency, strong flowering, balanced growth. A high-red spectrum (70%+) makes the most sense in a greenhouse, where the sun is already giving you lots of blue and green and your supplemental light can cast effective red to fill the gap.

Where does the ETS MAX series fit in?
This is the thinking behind the JumpLights ETS MAX series. Instead of forcing a spectrum into each room, it rarely comes up because a greenhouse and a high PPFD indoor flower room are not the same problem.

  • ETS MAX 4C41% red: for indoor rooms operating at very high intensity, where photobleaching is a real risk. The wider, red bottom balance allows you to push the tops without overcooking them
  • ETS MAX 4A48% red: balanced internal spectrum that maintains high output while controlling bleaching.
  • ETS MAX 5B57% Red: A high-performance indoor option. Moderate red, marked with efficiency and flower at the same time, up to 3,450 μmol/s, with efficiency that holds the spectrum.
  • ETS MAX 7A76% red: built for the greenhouse. The sun already supplies blue and green, so this leans heavily on the complementary red, up to 3,900 μmol/s in the infrastructure most greenhouses already have in place.

Bottom line
Choosing an activity is not a competition for the highest red number. The winning spectrum is the one that matches your environment, your intensity, your genetics, and what you’re trying to produce. Combine spectrum, intensity, environmental control, light distribution and genetics, and you’ve got a lighting strategy. Keep a spec isolated and all you’ve got is a bright room.

The ETS MAX line was created around this idea: choose the spectrum of the room you actually have, indoor or greenhouse, and let the device work with your grow rather than against it.

For more information:
JumpLights
www.jumplights.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media